Literature DB >> 1631151

An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma.

Y Sun1, G Hegamyer, Y J Cheng, A Hildesheim, J Y Chen, I H Chen, Y Cao, K T Yao, N H Colburn.   

Abstract

Point mutations in the p53 gene have been detected in a variety of human cancers; the mutations are clustered in four "hot-spots" located in the coding region of exons 5, 7, and 8, which coincide with the four most highly conserved regions of the gene. We report the finding of a heterozygous G----C mutation at codon 280 (exon 8), position 2, of the p53 gene in a nasopharyngeal carcinoma (NPC) cell line, originating from Guangdong, a province in the People's Republic of China that leads the world in NPC incidence. A survey of nasopharyngeal tissues and NPC biopsies revealed that 1 out of 12 NPC samples from Hunan, another province in the People's Republic of China with high NPC incidence, had the same heterozygous mutation at codon 280 of p53, and none of 10 biopsies from Taiwan showed a mutation within exons 5-8 of the p53 gene. No other alteration of gene structure, including gross rearrangement or loss of heterozygosity or abnormality of gene expression was detected in NPC cell lines or NPC biopsies. We conclude from this study that mutational or other alterations of the p53 gene are not common in nasopharyngeal carcinogenesis and that a codon-280 mutation of p53 may be involved in less than 10% of NPC cases. This result contrasts with the relatively high frequency of p53 mutations associated with several other human carcinomas and suggests the importance of other genes in NPC genesis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1631151      PMCID: PMC49532          DOI: 10.1073/pnas.89.14.6516

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  A simple method using PCR for direct sequencing of genomic DNA from frozen tumor tissue embedded in optimal cutting temperature compound.

Authors:  Y Sun; G Hegamyer; N H Colburn
Journal:  Biotechniques       Date:  1992-05       Impact factor: 1.993

2.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

Authors:  G Gaidano; P Ballerini; J Z Gong; G Inghirami; A Neri; E W Newcomb; I T Magrath; D M Knowles; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

3.  Mutations in the p53 gene in primary human breast cancers.

Authors:  R J Osborne; G R Merlo; T Mitsudomi; T Venesio; D S Liscia; A P Cappa; I Chiba; T Takahashi; M M Nau; R Callahan
Journal:  Cancer Res       Date:  1991-11-15       Impact factor: 12.701

4.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.

Authors:  B Bressac; M Kew; J Wands; M Ozturk
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

5.  Isolation and partial characterization of a transformation-associated sequence from human nasopharyngeal carcinoma.

Authors:  Y Cao; Y Sun; S Poirier; D Winterstein; G Hegamyer; J Seed; S Malin; N H Colburn
Journal:  Mol Carcinog       Date:  1991       Impact factor: 4.784

6.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

Authors:  I C Hsu; R A Metcalf; T Sun; J A Welsh; N J Wang; C C Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

7.  Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.

Authors:  P A Wright; N R Lemoine; P E Goretzki; F S Wyllie; J Bond; C Hughes; H D Röher; E D Williams; D Wynford-Thomas
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

8.  p53 mutations in ovarian cancer: a late event?

Authors:  R Mazars; P Pujol; T Maudelonde; P Jeanteur; C Theillet
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

Review 9.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

10.  p53 is frequently mutated in Burkitt's lymphoma cell lines.

Authors:  P J Farrell; G J Allan; F Shanahan; K H Vousden; T Crook
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

View more
  43 in total

1.  Upregulation of tyrosine kinase TKT by the Epstein-Barr virus transactivator Zta.

Authors:  J Lu; S Y Chen; H H Chua; Y S Liu; Y T Huang; Y Chang; J Y Chen; T S Sheen; C H Tsai
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 2.  Epstein-Barr virus and gastric carcinoma.

Authors:  K Takada
Journal:  Mol Pathol       Date:  2000-10

3.  Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection.

Authors:  Nirojini Sivachandran; Xueqi Wang; Lori Frappier
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

Review 4.  Involvement of the Epstein-Barr virus in the nasopharyngeal carcinoma pathogenesis.

Authors:  Javier S Burgos
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

5.  Changes in the nasopharyngeal carcinoma nuclear proteome induced by the EBNA1 protein of Epstein-Barr virus reveal potential roles for EBNA1 in metastasis and oxidative stress responses.

Authors:  Jennifer Yinuo Cao; Sheila Mansouri; Lori Frappier
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

6.  The genomic landscape of nasopharyngeal carcinoma.

Authors:  De-Chen Lin; Xuan Meng; Masaharu Hazawa; Yasunobu Nagata; Ana Maria Varela; Liang Xu; Yusuke Sato; Li-Zhen Liu; Ling-Wen Ding; Arjun Sharma; Boon Cher Goh; Soo Chin Lee; Bengt Fredrik Petersson; Feng Gang Yu; Paul Macary; Min Zin Oo; Chan Soh Ha; Henry Yang; Seishi Ogawa; Kwok Seng Loh; H Phillip Koeffler
Journal:  Nat Genet       Date:  2014-06-22       Impact factor: 38.330

7.  Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity.

Authors:  W Chen; N R Cooper
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

8.  Identification of a novel protein interaction motif in the regulatory subunit of casein kinase 2.

Authors:  Jennifer Yinuo Cao; Kathy Shire; Cameron Landry; Gerald D Gish; Tony Pawson; Lori Frappier
Journal:  Mol Cell Biol       Date:  2013-11-11       Impact factor: 4.272

9.  Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation.

Authors:  Bo Hong; Vivian W Y Lui; Edwin P Hui; Margaret H L Ng; Suk-Hang Cheng; Fion L Sung; Chi-Man Tsang; Sai-Wah Tsao; Anthony Tak-Cheung Chan
Journal:  Invest New Drugs       Date:  2009-12-16       Impact factor: 3.850

10.  Mitotic chromosome interactions of Epstein-Barr nuclear antigen 1 (EBNA1) and human EBNA1-binding protein 2 (EBP2).

Authors:  Vipra Kapur Nayyar; Kathy Shire; Lori Frappier
Journal:  J Cell Sci       Date:  2009-11-03       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.